EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments – Pharmaceutical Technology
Many significant Phase I-III studies targeting haematological malignancies, such as multiple myeloma (MM), were presented at the European Hematology Association Hybrid Congress 2024 (EHA 2024),